Gain-of-Function Mutations of ARHGAP31, a Cdc42/Rac1 GTPase Regulator, Cause Syndromic Cutis Aplasia and Limb Anomalies by Southgate, L et al.
Gain-of-Function Mutations of ARHGAP31, a Cdc42/Rac1 GTPase
Regulator, Cause Syndromic Cutis Aplasia and Limb Anomalies
Southgate, L; Machado, RD; Snape, KM; Primeau, M; Dafou, D; Ruddy, DM; Branney, PA;
Fisher, M; Lee, GJ; Simpson, MA; He, Y; Bradshaw, TY; Blaumeiser, B; Winship, WS;
Reardon, W; Maher, ER; FitzPatrick, DR; Wuyts, W; Zenker, M; Lamarche-Vane, N;
Trembath, RC
 
 
 
 
 
Copyright © 2011 The American Society of Human Genetics. Published by Elsevier Inc. All
rights reserved.
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/11530
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
1 
Gain-of-Function Mutations of ARHGAP31, a Cdc42/Rac1 
GTPase Regulator, Cause Syndromic Cutis Aplasia and 
Limb Anomalies 
 
Laura Southgate,
1,12
 Rajiv D. Machado,
1,12
 Katie M. Snape,
1,12
 Martin Primeau,
2
 Dimitra 
Dafou,
1
 Deborah M. Ruddy,
3
 Peter A. Branney,
4
 Malcolm Fisher,
4
 Grace J. Lee,
1
 Michael 
A. Simpson,
1
 Yi He,
2
 Teisha Y. Bradshaw,
1
 Bettina Blaumeiser,
5
 William S. Winship,
6
 
Willie Reardon,
7
 Eamonn R. Maher,
8,9
 David R. FitzPatrick,
4
 Wim Wuyts,
5
 Martin 
Zenker,
10,11
 Nathalie Lamarche-Vane
2
 and Richard C. Trembath
1,3,
* 
 
Author affiliations: 
1King’s College London, Department of Medical and Molecular Genetics, School of Medicine, 
Guy’s Hospital, London, SE1 9RT, United Kingdom; 2McGill University, Department of 
Anatomy and Cell Biology, 3640 University Street, Montreal, Quebec, Canada; 
3
Department of 
Clinical Genetics, Guy’s Hospital, London, SE1 9RT, United Kingdom; 4MRC Human Genetics 
Unit, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, United Kingdom; 
5
Department of Medical Genetics, University and University Hospital of Antwerp, Prins 
Boudewijnlaan 43, 2650 Edegem, Belgium; 
6
Nelson R Mandela School of Medicine, Faculty of 
Health Sciences, Department of Paediatrics and Child Health, University of KwaZulu-Natal, 
Durban 4041, South Africa; 
7
National Centre for Medical Genetics, Our Lady's Hospital for Sick 
Children, Crumlin, Dublin 12, Ireland; 
8
Medical and Molecular Genetics, School of Clinical and 
Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, 
Institute of Biomedical Research, Birmingham, B15 2TT, United Kingdom; 
9
West Midlands 
Regional Genetics Service, Birmingham Women's Hospital, Birmingham, B15 2TG, United 
Kingdom; 
10
Institute of Human Genetics, University Hospital Erlangen, University of Erlangen-
Nuremberg, Schwabachanlage 10, 91054, Erlangen, Germany; 
11
Institute of Human Genetics, 
University Hospital Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany 
12
These authors contributed equally to this work 
*Correspondence: richard.trembath@kcl.ac.uk 
 
2 
ABSTRACT 
Regulation of cell proliferation and motility is essential for normal development. The Rho 
family of GTPases plays a critical role in the control of cell polarity and migration 
through effects upon the cytoskeleton, membrane trafficking and cell adhesion. We 
investigated a recognized developmental disorder, Adams-Oliver syndrome (AOS), 
characterized by the combination of aplasia cutis congenita (ACC) and terminal 
transverse limb defects (TTLD). Through a genome-wide linkage analysis, we detected a 
locus for autosomal dominant ACC-TTLD on a region of chromosome 3q, generating a 
maximum LOD score of 4.93 at marker rs1464311. Candidate gene and exome-based 
sequencing led to the identification of independent premature truncating mutations in the 
terminal exon of the Rho GTPase-activating protein 31 (ARHGAP31) gene, which 
encodes a Cdc42/Rac1 regulatory protein. Mutant transcripts are stable and increase 
ARHGAP31 activity in vitro through a gain-of-function mechanism. Constitutively active 
ARHGAP31 mutations result in a loss of available active Cdc42 and consequently disrupt 
actin cytoskeletal structures. Arhgap31 expression in the mouse is substantially restricted 
to the terminal limb buds and craniofacial processes during early development, closely 
mirroring the sites of impaired organogenesis that characterize this syndrome. These data 
identify the requirement for regulated Cdc42/Rac1 signaling processes during early 
human development. 
 
 
 
 
 
 
3 
INTRODUCTION 
Members of the large family of GTPases act as molecular switches that control many 
aspects of cell activity, through a remarkably simple biochemical mechanism of cycling 
between two conformational forms. The ‘active’ state requires bound guanosine 
triphosphate (GTP) to allow interaction with one of many effector proteins, whereas the 
GTPase-mediated hydrolysis of GTP to guanosine diphosphate (GDP) engenders an 
inactive state.
1
 Whilst the Rho switch appears straightforward, the process is closely 
controlled by at least three classes of regulators, namely guanine nucleotide exchange 
factors (GEFs), GTPase-activating proteins (GAPs) and GDP dissociation inhibitors 
(GDIs). The Rho GTPases, which include Cdc42 and Rac1, hold central functions in cell 
division, survival and migration, and alterations in expression have been widely studied in 
cancer, indicating a role in tumor invasion and metastasis.
2
 However, regulation of cell 
proliferation and migration are also fundamental aspects of organ formation, especially 
during early developmental stages. We have studied an inherited disorder characterized 
by abnormalities of limb development, a recognized paradigm of human organogenesis, 
and report a GAP regulatory defect as the primary cause. 
Adams-Oliver syndrome (AOS [MIM 100300]) describes the congenital absence of skin, 
aplasia cutis congenita (ACC), in combination with terminal transverse limb defects 
(TTLD) (Figure 1A). Limb abnormalities typically affect the distal phalanges or entire 
digits and, rarely, more proximal limb structures. Important associated anomalies include 
vascular cutis marmorata and cardiac and vascular abnormalities, for example pulmonary 
hypertension.
3
 Whilst the combination of ACC and TTLD most often occurs in sporadic 
cases, segregation within families is consistent with autosomal dominant inheritance in 
some kindred and autosomal recessive in others. Variability of the disease phenotype is 
also widely recognized, including an absence of either of the major features in obligate 
4 
carriers, indicating reduced penetrance of the disease allele. Clinically, in cases with a 
known family history, the presence of either ACC or TTLD has been considered 
sufficient to make the diagnosis of AOS.
3
 
We have now used genome-wide linkage analysis to study two kindreds with autosomal 
dominant ACC-TTLD and subsequently identified heterozygous mutations in a RhoGAP 
family member, Rho GTPase-activating protein 31 (ARHGAP31 [MIM 610911]), also 
known as Cdc42 GTPase-activating protein (CdGAP),
4
 by candidate gene and exome 
sequencing. We determined the distribution of expression of Arhgap31 during 
development and verified the pathogenic effect of these mutations in primary human 
dermal fibroblasts from patients with ACC-TTLD. This genetic finding identifies the 
importance of Cdc42/Rac1 pathways in the developmental processes of scalp and limb 
formation. 
 
 
SUBJECTS AND METHODS 
Clinical ascertainment 
Index subjects were recruited through specialist clinical genetics centers from within the 
UK and Europe, and via the Adams-Oliver Syndrome Support Group, UK. Additional 
family members, including unaffected individuals and spouses, were then invited to 
participate in the study. All participants underwent a detailed physical examination by 
experienced clinical geneticists. A diagnosis of ACC-TTLD was based on clinical 
guidelines
3
 and supported by radiological investigations in selected patients. Kindreds 
AOS-5 and -12 are previously reported in the medical literature
5,6
 and were updated in 
2009.
3
 All subjects gave written informed consent in accordance with the protocol 
approved by the Guy’s and St Thomas’ NHS Foundation Trust local research ethics 
5 
committee. 
 
Genotyping, linkage analysis and mutation detection 
Genomic DNA was extracted from peripheral venous blood by standard techniques or 
from saliva using the Oragene-DNA self-collection kit (DNA Genotek Inc). A genome-
wide screen was performed for 22 individuals from two multigenerational families, using 
the GoldenGate HumanLinkage V Panel on an iScan System (Illumina Inc), following 
manufacturer’s guidelines. Linkage analysis was performed using Merlin v1.1.2 software, 
under an autosomal dominant disease model with a disease allele frequency of 0.0001 and 
a penetrance value of 85%. Additional polymorphic markers for refinement mapping 
were selected with an average heterozygosity of 74%. Fluorescently-tagged polymerase 
chain reaction (PCR) fragments were analyzed on an ABI3730xl DNA Analyzer and 
genotypes were assigned using GeneMapper v3.7 software (Applied Biosystems). 
All coding exons and intron-exon boundaries of the candidate genes ARHGAP31, GSK3B 
[MIM 605004], LSAMP [MIM 603241], and POPDC2 [MIM 605823] were screened by 
direct DNA sequencing. Primers were designed using Primer3 software.
7
 PCR products 
were purified with ExoSAP-IT (GE Healthcare) and sequenced using BigDye Terminator 
v3.1 chemistry (Applied Biosystems). Sequence traces were aligned to reference using 
Sequencher v4.9 software (Gene Codes Corporation). 
Exome capture of subject III:2 (Figure 1B) was undertaken using the SureSelect Target 
Enrichment System (Agilent) and sequenced on a Genome Analyzer IIx (Illumina). 
Paired-end sequence reads were aligned to the reference genome (hg18) using Novoalign 
software (Novocraft Technologies Sdn Bhd). Duplicate reads, resulting from PCR 
clonality or optical duplicates, and reads mapping to multiple locations were excluded 
from downstream analysis. Single nucleotide substitutions and small insertion deletions 
6 
were identified and quality filtered within the SamTools software package
8
 and in-house 
software tools.
9
 Variants were annotated with respect to genes and transcripts with the 
SNPClassifier tool.
10
 Filtering of variants for novelty was performed by comparison to 
dbSNP131 and 1000 Genomes pilot SNP calls (March 2010). The accession numbers of 
the reference sequences used for mutation nomenclature are NM_020754.2 (mRNA) and 
NP_065805.2 (protein). 
 
Gene expression analysis 
Fetal expression of ARHGAP31 was assessed using a human fetal multiple tissue cDNA 
(MTC) panel (Clontech). PCR was performed using standard protocols with primers 
ARHGAP31_3Fw (5′ AGCTCATGTGACCTCACCAA 3′) and ARHGAP31_3Rv (5′ 
AGACTGGAGCAGGGAAGGAG 3′) to generate a 976 bp fragment. GAPDH primers 
(Clontech) were used as an internal control. 
For reverse-transcription PCR (RT-PCR), cDNA was generated from 1 μg of RNA 
extracted from patient and wild-type (WT) EBV-transformed lymphoblasts, using the 
Verso cDNA kit (ABgene). Real-time quantitative PCR was performed using ARHGAP31 
Taqman gene expression probes according to the standard protocol on a Real-time PCR 
7900HT (Applied Biosystems). GAPDH (Applied Biosystems) was used as an 
endogenous control. Relative levels of gene expression were calculated by SDS v2.2 
software (Applied Biosystems) using the Comparative CT method of data analysis 
(Relative Quantity = 2 -ΔΔCt). 
 
Whole-mount in situ hybridization 
The genomic sequence of Arhgap31 was obtained from Ensembl. Primers were designed 
using Primer3 software
7
 to produce a PCR product of 543 bp from the 3′ UTR of 
7 
Arhgap31 (genomic location: chr16:38,599,795-38,600,337). T3 and T7 RNA 
polymerase sites were added to the 5′ end of the forward and reverse primers respectively 
(forward: 5′ AATTAACCCTCACTAAAGGCTGCTGGAGGAAGGTTTCTG 3′; reverse: 
5′ TAATACGACTCACTATAGGCGCCTCTCCACACCATATTT 3′). Digoxigenin (DIG) 
labeled (Roche Applied Science) antisense riboprobes were generated by in vitro 
transcription of purified PCR-amplified DNA template using T7 RNA polymerase. 
CD1 mouse embryos at developmental stages 9.5, 10.5, 11.5 and 12.5 days post-coitum 
(dpc) were obtained from the Mary Lyon Centre, MRC Harwell, UK. Embryos were fixed 
overnight in 4% paraformaldehyde at 4 °C, stored in methanol and rehydrated in a series 
of graded methanol washes in PBST (PBS + 0.1% Tween 20). Proteinase K (10 μg/ml) 
(Roche Applied Science) permeabilization was performed for 15-35 min, depending on 
the stage of development. Embryos were washed twice in 0.1 M triethanolamine, with the 
addition of acetic anhydride to the second wash. Samples were then washed in PBST and 
re-fixed in 4% PFA/0.2% gluteraldehyde for 20 min. Following washing in PBST, 
embryos were pre-hybridized for 2 h at 60 °C and hybridized for 48 h at 60 °C in 
hybridization buffer containing the DIG-labeled probe. Samples were washed for 3 × 20 
min in 2 × SSC + Tween 20 and then 3 × 30 min in 0.2 × SSC + 0.1% Tween 20 at 60 °C. 
Samples were then washed 2 × 15 min in maleic acid buffer (MAB) at room temperature. 
A final wash for 2 h in MAB + 2% Boehringer-Mannheim blocking reagent (BMB) + 
20% heat-treated lamb serum solution at room temperature was performed before 
overnight incubation in the same solution containing a 1/2000 dilution of anti-DIG 
antibody coupled to alkaline phosphatase (Roche Applied Science). Embryos were then 
washed for 3 × 1 h in MAB and color detected with 2 ml of BM purple precipitating 
solution (Roche Applied Science). 
 
8 
Optical projection tomography 
Whole-mount in situ hybridization (WISH) was performed as described above. Embryos 
were mounted in 1% agarose, dehydrated in methanol and then cleared overnight in 
BABB (1 part Benzyl Alcohol: 2 parts Benzyl Benzoate). Samples were then imaged 
using a Bioptonics optical projection tomography (OPT) Scanner 3001 using brightfield 
to detect the staining and for tissue autofluorescence (excitation 425nm, emission 475nm) 
to capture the anatomy.
11
 The resulting images were reconstructed using Bioptonics 
proprietary software, automatically thresholded and merged to a single 3D image output 
using Bioptonics Viewer software. The downstream digital dissection and sectioning 
were performed using Amira software (Visage Imaging). 
 
Cloning and mutagenesis 
Full-length myc-tagged ARHGAP31 was generated as previously described.
4
 Mutant 
constructs were engineered by performing site-directed mutagenesis with the 
QuickChange kit (Stratagene) on the WT template. Primers are available on request. 
 
Cell culture 
Cells were maintained at 37 °C in a humidified incubator with 5% CO2. Human 
endometrioid cancer (HeLa, ATCC) and human embryonic kidney (HEK293) cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 4.5 g/ml 
GlutaMax and 10% heat inactivated fetal bovine serum (FBS). EBV-transformed 
lymphoblasts (ECACC) from a WT control and ACC-TTLD patients with and without 
ARHGAP31 mutations were cultured in RPMI-1640 supplemented with 10% heat 
inactivated FBS. Human primary dermal fibroblast cells were established from 4 mm 
tissue biopsies from a WT control individual and an ACC-TTLD patient carrying the 
9 
p.Gln683X mutation. Tissues were enzymatically dissociated using accutase and 
fibroblasts were grown in basal medium 106 supplemented with 2% (v/v) FBS, 1 μg/ml 
hydrocortisone, 10 ng/ml human epidermal growth factor, 3 ng/ml basic fibroblast growth 
factor, and 10 μg/ml heparin. Normal human neonatal dermal fibroblasts (HDF, Lonza), 
used as an additional control for proliferation assays, were cultured under the same 
conditions as described above. All cell culture reagents were obtained from Invitrogen. 
Transient transfections of HeLa cells were performed using FuGENE (Roche) in 
accordance with manufacturer’s instructions, using a 3:1 ratio of transfection reagent to 
DNA. 
 
Immunofluorescence 
HeLa cells and fibroblasts were plated in 6-well plates (Corning) on acid-treated glass 
coverslips (Laboratory Sales Limited) and allowed to grow until 80% confluent. Cells 
were fixed in ice-cold methanol, rehydrated with 1 × PBS, and blocked with a 0.5% BSA 
(Sigma-Aldrich) in 1 × PBS solution. Following blocking, cells were incubated with a 
polyclonal rabbit antibody raised against a peptide corresponding to amino acids 541-562 
of mouse Arhgap31 (PRD1) and purified on a Protein A-Sepharose column (1:500 
dilution). After washing with blocking solution, a secondary rabbit-specific fluorophore-
tagged antibody (Abcam Inc.) was added for 1 h. Coverslips were rinsed and mounted on 
slides with hard-set mounting medium containing a DAPI nuclear stain (Vector Labs). 
Golgi and cytoskeleton visualization were performed using 58K Golgi protein and 
monoclonal tubulin antibodies (Abcam Inc.), respectively. Antibodies were diluted 
according to manufacturer's instructions. PRD1 antibody specificity tests were performed 
using preimmune serum from the antibody host rabbit in place of the Arhgap31 antibody. 
A second specificity test utilized a blocking peptide specific to the PRD1 antibody 
10 
epitope used at a 10:1 concentration (peptide to antibody). We further used a blocking 
peptide specific to a random region of Arhgap31 as an additional negative control. Both 
blocking peptides were synthesized by Sigma-Aldrich. All images were acquired on a 
Zeiss LSM 510 confocal microscope and processed with Adobe Photoshop. Statistical 
comparisons for cell rounding experiments were conducted using a Fisher’s exact test. 
 
G-LISA Cdc42 activation assay 
HEK293 cells were grown to 70% confluency on 100 mm dishes and transiently 
transfected using polyethyleneimine (Polysciences Inc.) with 100 ng of empty vector 
DNA or vector encoding myc-tagged WT ARHGAP31, p.Lys1087SerfsX4 or p.Gln683X. 
Cells were lysed 16 h post-transfection according to manufacturer’s instructions 
(Cytoskeleton Inc.) and snap-frozen in liquid nitrogen. Levels of tagged proteins and 
Cdc42 were determined by Western blotting using polyclonal myc-specific (Cell 
Signaling Technology) and Cdc42-specific (Santa Cruz Biotechnology) antibodies, 
respectively. The relative amounts of GTP-bound Cdc42 in each condition were 
determined in duplicate. For each Cdc42-GTP measurement, 100 μg of protein lysate was 
used. To compare WT and mutant ARHGAP31 activity, a student’s t-test was used with a 
two-tail distribution. 
 
Immunoprecipitation 
HEK293 cells were co-transfected with mouse pRK5myc-Arhgap31 (1083-1425) and 
pEGFP-Arhgap31 (1-221 or 1-820). After 16 h, cells were lysed on ice in 25 mM HEPES 
pH 7.4, 100 mM NaCl, 10 mM MgCl2, 5% glycerol, 1% NP-40, 1 mM Na3VO4, 10 mM 
NaF, 1 mM PMSF and protease cocktail inhibitors (Roche Applied Science). Protein 
lysates were centrifuged for 10 min at 14,000 g and pre-cleared for 1 h at 4 °C with 
11 
Protein G-Sepharose (GE Healthcare). Supernatants were incubated for 3 h at 4 °C with 2 
μg of monoclonal myc-specific antibody (9E10) and Protein G-Sepharose. Immune 
complexes were washed three times in lysis buffer and resuspended in SDS sample 
buffer. Proteins were resolved by SDS-PAGE and detected by Western blotting using 
antibodies to GFP (A6455, Molecular probes) and myc. 
 
Proliferation assay 
The CyQUANT fluorescence-based microplate assay was used for quantitation of cell 
number. To generate a standard calibration curve, binding to cellular nucleic acids was 
measured using 485 nm (±10 nm) excitation and 530 nm (±12.5 nm) emission filters 
using a CytoFluor 2350 fluorescence microplate reader. The fluorescence emission of the 
dye-nucleic acid complexes was then correlated linearly with cell numbers from a dilution 
series ranging from 100 to 50 × 10
4
 cells, measured using a hemocytometer. 
Sample cells were lysed at room temperature with 1 ml of CyQUANT GR dye/lysis 
buffer and incubated in darkness for 2-5 min at room temperature. 6-well culture plates of 
cells were harvested on days 1-9 and lysed with 200 μl of CyQUANT GR dye/lysis buffer. 
Sample fluorescence was measured, and growth curves were plotted as cell number over 
time in culture. For each independent control (WT and HDF), an unpaired t-test was used 
to compare cultured cell numbers with the patient (p.Gln683X) sample at each time point. 
 
Wound healing assay 
Wound healing assays were performed using WT and p.Gln683X primary dermal 
fibroblast cells plated on fibronectin-coated 35 mm tissue culture dishes with an IBIDI 
chamber at a density of 8500 cells/well. Cells were serum and growth supplement starved 
for 12 h, before removing the cells from half of each well using a sterile rubber policeman. 
12 
Wounding was performed after 12 h incubation, cultures were washed twice with 1 × 
PBS and wound margins were photographed (t=0 h). The same wound margin fields were 
photographed at different time points, pictures were superimposed and areas were 
measured using Image J software. 
 
 
RESULTS 
Genome-wide mapping and identification of ARHGAP31 mutations 
Linkage analysis identified a locus for ACC-TTLD on chromosome 3q13.31-q13.33 
(Figure S1). Subsequent refinement mapping defined a 5.53 Mb critical interval flanked 
by markers rs714697 and D3S4523, containing a total of 21 protein-coding genes and 3 
open-reading frames (Figure S2). We sequenced four genes in affected members of the 
linked AOS-5 and AOS-12 families. In each kindred we identified a distinct sequence 
variant (c.2047C>T and c.3260delA) within the terminal coding exon of ARHGAP31, that 
segregate with the syndrome phenotype and predict the formation of premature truncating 
mutations (p.Gln683X and p.Lys1087SerfsX4) (Figure 1B, C). No likely disease causing 
sequence variants were detected in the other genes analyzed. To comprehensively exclude 
the existence of pathogenic mutation in the linked interval, we performed whole exome 
sequencing in one individual from Family AOS-12, and verified the c.2047C>T 
ARHGAP31 nonsense mutation as the only novel variant within the extended 13.2 Mb 
linkage region (Figure S2). 
We screened ARHGAP31 by DNA sequencing in affected members of a further three 
multiplex kindreds, unlinked to the chromosome 3 locus, and a cohort of 43 sporadic 
individuals with features of ACC and TTLD, either alone or in combination. A non-
synonymous polymorphism (c.2180C>T; p.Thr727Ile) was detected in two sporadic cases, 
13 
but no pathogenic sequence variants were identified in this extended cohort. To exclude 
the possibility that the truncating variants were also polymorphisms, or that ARHGAP31 
harbors frequent but functionally insignificant variation, we re-sequenced all 12 exons in 
72 unrelated control individuals. None of these individuals carried either of the likely 
disease-causing ARHGAP31 mutations or any other missense or splice-site variants. We 
additionally sequenced exon 12, the site of the putative disease-causing mutations, in a 
further 1,138 unrelated control subjects of European origin. Whilst the c.2180C>T 
polymorphism was detected in two control subjects, neither of the ACC-TTLD truncating 
mutations was detected in the combined total of over 2,000 chromosomes assayed. 
 
ARHGAP31 expression during early development 
Analysis of ARHGAP31 transcript expression showed abundant and ubiquitous levels in 
all human fetal tissues examined (Figure S3). To determine the regional expression of 
Arhgap31 mRNA, we studied mouse embryos during early development (Figure 2). At 
9.5 dpc, the strongest expression is in the developing heart, with regional localization to 
the ventral walls of primitive ventricle and primitive atrium (Figures 2A and 2B). By 10.5 
dpc, Arhgap31 expression becomes largely restricted to the lateral walls of the developing 
ventricle, with expression in the primitive atrium becoming localized to its outer wall 
(Figures 2C and 2D). At 11.5 dpc, Arhgap31 expression is largely restricted to the surface 
ectoderm with strong expression overlying the entire heart field, symmetrical regions of 
the head and flank and the apical regions of the hand and foot plates (Figures 2E and 2F). 
By 12.5 dpc, the expression in the surface ectoderm is not detectable by WISH (data not 
shown). 
 
 
14 
Effect of ARHGAP31 mutations 
To determine the impact of exon 12 mutations predicting premature termination during 
translation (Figure 3A), we assessed transcript stability by quantitative RT-PCR of RNA 
extracted from lymphoblasts. A comparison between WT control and two related subjects, 
both heterozygous for the c.2047C>T (p.Gln683X) mutation, showed no reduction in the 
abundance of ARHGAP31 transcript, in support of the hypothesis that the mutant 
transcript is not removed by the process of nonsense-mediated decay (Figure 3B). 
Since the antibody to ARHGAP31 was unsuitable for protein detection by Western blot 
analysis, we used immunofluorescence and found ARHGAP31 predominantly localized 
to the Golgi. We found no indication of protein degradation, such as loss of staining 
intensity or aggregate formation, and ARHGAP31 localization appeared normal in ACC-
TTLD primary fibroblasts that harbor the p.Gln683X mutant protein (Figure 3C). 
However, subtle differences in localization or indeed organelle morphology, whilst not 
qualitatively evident, cannot be excluded. 
ARHGAP31 is a member of the RhoGAP family of proteins known to inactivate the Rho 
GTPases Cdc42 and Rac1.
4
 Thus, we next investigated the impact of truncation of 
ARHGAP31 on GAP activity. We performed in vitro experiments in HEK293 cells and 
found that, relative to full-length ARHGAP31, both truncated proteins displayed a 
marked augmentation of GAP activity upon Cdc42, resulting in a significant down-
regulation of the active GTPase (Figure 4A). We conclude that both disease mutations in 
ARHGAP31 behave as dominant gain-of-function alleles. 
The ARHGAP31 mutations associated with the ACC-TTLD phenotype result in the 
removal of the C-terminal tail. To test the possibility that the C-terminus of ARHGAP31 
affects the GAP activity through intra-molecular interactions, we generated green 
fluorescent protein (GFP) tagged ARHGAP31 deletion constructs to perform protein 
15 
immunoprecipitation studies in HEK293 cells with a myc-tagged construct encoding the 
C-terminus. Indeed, we found that the C-terminus of ARHGAP31 is able to interact with 
the N-terminus region (amino acids 1-820), and we further refined the interaction to a 
region comprising the RhoGAP domain (amino acids 1-221). Although our data do not 
exclude the possibility that the C-terminus may also bind a second motif downstream of 
the RhoGAP domain, these results indicate the potential for an auto-regulation 
mechanism (Figure 4B). 
 
In vitro phenotypic analysis of mutant ARHGAP31  
Perturbation of Cdc42/Rac1 signaling pathways impacts directly upon cell proliferation 
and migration in a cell-specific manner.
12,13
 Therefore, we hypothesized that the ACC-
TTLD defects would impact upon cell proliferation and ordered cell migration. Following 
p.Gln683X fibroblasts over a 9-day period revealed a significantly reduced rate of cell 
proliferation (Figure 5A). In addition, we performed wound healing assays with the 
mutant fibroblasts, which showed significant differences in cell migration, suggestive of 
altered cell motility (Figures 5B and 5C). The rounding of cells is a characteristic of 
impairment of the ordered process of actin polymerization and associated to a specific 
mode of cell movement during tumor cell migration.
13
 Transient transfection of disease-
causing ARHGAP31 constructs induced a rounded phenotype in a significant proportion 
of HeLa cells, in keeping with recent observations of suppressed Cdc42 activity (Figures 
5D and 5E).
14
 However, cytoskeletal organization as assessed by F-actin staining of 
human fibroblasts heterozygous for the p.Gln683X mutation was not qualitatively distinct 
from controls, presumably due to dosage compensation by the wild-type allele (data not 
shown). 
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DISCUSSION 
Fundamental insight as to necessary signaling pathways requisite to normal limb 
patterning and outgrowth has primarily been gained from the study of model organisms 
and inherited disorders of limb formation.
15,16
 The fibroblast growth factor (FGF), bone 
morphogenetic protein (BMP), hedgehog and Wnt protein families have all been 
implicated in this important paradigm of organogenesis. Spatial and temporal expression 
of these signaling molecules is critical. For example, in the apical ectodermal ridge 
(AER), a specialized epithelium located along the distal tip of the limb bud, molecular 
signals generated by several members of the Fgf family control limb outgrowth and 
proximal-distal patterning.
17
 Wnt signals interact with FGFs in the AER to maintain 
mesenchymal progenitors in an undifferentiated, proliferative state.
18
 By contrast, the 
expression of BMP ligands regulates dorsal-ventral patterning and interdigital cell 
death,
19
 and inhibits sonic hedgehog transcription through disruption of FGF and Wnt 
signaling.
20
 Further delineating the crosstalk and interaction between such genes and 
pathways is required to establish an integrative model of limb organogenesis; however, 
additional critical steps remain to be elucidated.
15
 
In this study, we have used a classical positional cloning approach in conjunction with the 
contemporary technology of exome sequencing,
21
 to identify distinct truncating mutations 
within the terminal exon of ARHGAP31. Combining candidate gene analysis with large-
scale exome sequencing now provides an opportunity for rapid detection of genes in 
Mendelian disease. Importantly, we have shown that this strategy can be successful using 
exome data from a single affected individual, and have been able to verify truncating 
mutations of ARHGAP31 as the only novel variation within our extended linkage interval. 
The clinical phenotypes in the two kindreds with ARHGAP31 mutations share a number 
17 
of features. Both mutations are associated with scalp aplasia cutis congenita and 
upper/lower limb defects of significant variability and reduced penetrance, including 
short distal phalanges, partial absence of the fingers and toes and cutaneous syndactyly of 
toes 2-3 (Figures 1B and 1C). Using whole-mount in situ hybridization and optical 
projection tomography in mouse embryos, we have detected Arhgap31 transcript 
expression in distinct regions of the surface ectoderm, including the head and upper and 
lower limb buds, at 11.5 dpc. Expression in the distal tip of the limb buds during late 
stages of embryonic development would be consistent with a role in limb outgrowth and 
proximal-distal patterning. Interestingly, and despite evident expression of Arhgap31 in 
the developing mouse heart, no affected subjects displayed evidence of congenital cardiac 
abnormalities, which is a widely recognized feature of the ACC-TTLD spectrum. To 
address this further, we screened ARHGAP31 in an extended panel of ACC-TTLD 
patients, with and without cardiac abnormalities. No additional mutations were identified, 
indicating that defects in ARHGAP31 account for only a small proportion of subjects with 
the ACC-TTLD spectrum of clinical features. Future studies will likely identify additional 
gene defects causative of AOS. 
Our data suggest the c.2047C>T nonsense mutation does not activate the nonsense-
mediated decay pathway, in keeping with premature termination codons downstream of 
the final splice junction.
22
 Immunofluorescence studies identified the expression and 
localization of mutant protein to be confined to the Golgi apparatus, a site of activity of 
Cdc42, at comparable levels as observed for wild-type ARHGAP31.
23
 The Rho family 
members Cdc42 and Rac1 are active when GTP bound. The hydrolysis of GTP, for 
example by ARHGAP31, leads to inactivation of Cdc42/Rac1 and, as such, intracellular 
Cdc42- and Rac1-GTP levels are inversely proportional to the activity of ARHGAP31. 
Measurements of GAP activity, as determined by G-LISA assays, demonstrated both 
18 
truncating mutations result in a significant down-regulation of active Cdc42, compatible 
with a dominant gain-of-function mechanism of these disease-causing alleles. 
Both the ARHGAP31 mutations associated with the ACC-TTLD phenotype are predicted 
to truncate the C-terminal tail. We postulated whether the C-terminus of ARHGAP31 was 
capable of interacting with the amino terminus so as to shield the RhoGAP domain, 
consistent with comparable auto-regulatory mechanisms reported for other members of 
GTPase pathways, for example p50RhoGAP, N-chimaerin, and the downstream signaling 
effectors WASP and PAK1.
24-27
 In this study, we demonstrate an interaction between the 
C-terminus of ARHGAP31 and the N-terminal RhoGAP domain, suggesting a model in 
which truncation of the ARHGAP31 C-terminal domain in mutant proteins would result 
in the exposure of a constitutively active RhoGAP catalytic site (Figure 6A). 
Perturbation of Cdc42 and/or Rac1 signaling impacts upon directed migration, 
proliferation and differentiation in a cell-specific manner.
12
 Constitutive inactivation of 
Cdc42 by GTPase inhibitors, for example VopS, leads to cell rounding due to disruption 
of the actin cytoskeleton.
14
 Furthermore, low Rac1 activity is associated with a rounded 
mode of cell movement.
28
 In this report, we demonstrate a very similar outcome for cell 
morphology upon transient over-expression of ARHGAP31 mutant proteins, and a 
significant disruption of cell migration in fibroblast mutant cells, pointing towards the 
unregulated suppression of Cdc42/Rac1 function. Importantly, ARHGAP31 has recently 
emerged as a regulator of Cdc42/Rac1 signaling to the cytoskeleton, thereby playing a 
key role in controlling the temporal and spatial cytoskeletal remodeling necessary for the 
precise control of cell morphology and migration.
29
 In addition, its GAP activity is 
regulated in an adhesion-dependent manner and appears to be required for normal cell 
spreading, polarized lamellipodia formation, and cell migration.
29
 Whilst the wound 
healing assays performed in this study do not measure the direction of cell movement, it 
19 
is feasible that the increased GAP activity in ARHGAP31 mutant fibroblasts leads to a 
loss of adhesion and/or structural defects in cell protrusion formation, regulated by Cdc42 
and Rac1,
30
 thus resulting in disorganized cell migration. A more comprehensive disease 
cell-based study aimed, in particular, at examining cytoskeletal dysfunction is now 
required to build on these early observations and further define the mechanisms driving 
pathogenesis in this disorder. 
Further insight into the wider ARHGAP31 signaling pathway is provided by a 
keratinocyte specific Cdc42 knock-out mouse model, which offers an integrated model 
for the molecular basis of the AOS phenotype.
31
 Mutant mice display cellular 
abnormalities of skin morphogenesis, phenotypically illustrated by progressive loss of 
hair follicles. Central to this process is the stabilization of β-catenin by Wnt and Cdc42 
signaling, which together inhibit the activity of glycogen synthase kinase 3 beta (GSK-
3β), a critical driver of β-catenin degradation.32 By contrast, ARHGAP31 levels are 
augmented by GSK-3β activity.33 We would suggest that in ACC-TTLD cells, the 
inactivation of Cdc42 by constitutively active mutant ARHGAP31 would compromise 
this critical negative feedback loop and result in upregulation of mutant ARHGAP31 by 
GSK-3β, concomitant de-stabilization of β-catenin with consequent impairment of 
cellular processes, in particular progenitor cell differentiation, requisite for skin layer and 
hair follicle production (Figures 6B and 6C). In addition to this, Rac1 activity has recently 
been implicated in nuclear localization of β-catenin during canonical Wnt signaling,34 and 
keratinocyte-restricted deletion has identified a critical role in hair follicle integrity.
35
 
More importantly, genetic removal of Rac1 in the mouse embryonic limb bud ectoderm 
disrupts Wnt signaling and results in severe truncations of the limb. Furthermore, 
conditional deletion of Rac1 in the mouse limb bud mesenchyme also leads to skeletal 
deformities including abnormal fusion of the skull, developmental limb defects and 
20 
syndactyly.
36
 These reports, combined with our ARHGAP31 study, demonstrate the 
crucial roles of Cdc42 and Rac1 in skin morphogenesis and limb development. Clearly 
further work will now be required, informed by our genetic findings, to further elucidate 
these early mechanistic insights and confirm the molecular processes proposed within this 
model. 
Taken together, our findings demonstrate that heterozygous gain-of-function mutations in 
ARHGAP31 cause an autosomal dominant form of ACC-TTLD through introduction of 
premature termination codons in the terminal exon of the gene. Expression of Arhgap31 
during development appears confined to the limb buds, cranium and early cardiac 
structures, providing a remarkable correlation with the developmental defects that define 
ACC-TTLD. This report generates insight into the critical pathways regulating the 
processes of cell proliferation and movement in vivo and the consequences for human 
health with dysregulation of skin and limb formation. 
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FIGURE TITLES AND LEGENDS 
Figure 1. Features of ACC-TTLD and segregation of ARHGAP31 mutations 
(A) Characteristic phenotype of ACC-TTLD, with severe ACC (left panels), and a range 
of TTLD defects of the hands (middle panels) and feet (right panels), including partial 
absence of the fingers and toes, and short distal phalanxes of fingers and toes. 
(B) Pedigree structure of Family AOS-12 showing segregation of the c.2047C>T 
nonsense mutation represented in the adjacent sequence chromatogram. 
(C) Segregation and sequence chromatogram of the c.3260delA frameshift mutation in 
Family AOS-5. Mutation carriers are denoted by + / –. 
Key to symbols: Aplasia cutis congenita;       Bony defect / abnormal fontanelle;    
 Terminal transverse limb defects;  Syndactyly;   Unsymptomatic mutation 
carrier;   Unaffected. 
 
Figure 2. Expression of Arhgap31 during mouse embryogenesis 
(A) Right lateral view of volume rendered OPT 3-dimensional representation of a 9.5 dpc 
27 
mouse embryo showing Arhgap31 expression (red) in developing heart (he). 
(B) Digital section of same embryo as A, showing expression in ventral wall of the early 
ventricle and atrium of the heart and the first pharyngeal arch (pa). 
(C) Frontal view of rendered, and (D) digital coronal section of 10.5 dpc mouse embryo 
with expression in the lateral walls of the early ventricles of the heart and the first 
pharyngeal arch derived facial mesenchyme (fm). 
(E and F) By 11.5 dpc the expression is restricted to distinct regions of the surface 
ectoderm (se), including the upper and lower limb bud (lbe). 
 
Figure 3. Transcript and protein expression in WT and mutant cells 
(A) Schematic of the ARHGAP31 structure, showing the position of the mutations 
identified in exon 12. The ARHGAP31 structure beneath depicts the known RhoGAP and 
proline-rich domains, a site of phosphorylation by GSK-3. 
(B) Real-time quantitative RT-PCR examining ARHGAP31 transcript levels in 
lymphoblasts from two related subjects heterozygous for the c.2047C>T (p.Gln683X) 
nonsense mutation, compared to a genotypically normal control (WT). Patient and control 
samples show no appreciable difference in transcript expression. Sample identifiers refer 
to the pedigree structure in Figure 1B. The ACC-TTLD control is a patient with no 
ARHGAP31 mutation (molecular genetic basis unknown). Data represent mean ± SD 
from 3 independent experiments. RQ = Relative quantification. 
(C) Immunostaining of (i) endogenous ARHGAP31 (red) and (ii) Golgi (green), with 
marked levels of co-localization to the Golgi apparatus in HeLa cells (iii). The nucleus is 
stained in blue. Images in the inset boxes show a 3× higher magnification of the single 
cell marked by the dashed lines. (iv) The high specificity of the ARHGAP31 antibody is 
indicated by the absence of staining in the presence of blocking peptide to the binding 
28 
epitope. In both (v) WT and (vi) mutant (p.Gln683X) fibroblasts, ARHGAP31 (green) 
localizes to the Golgi (red) and appears identical and of equivalent intensity. Inset boxes 
show 3× higher magnifications of the single cells marked. 
 
Figure 4. Analysis of GAP activity in ARHGAP31 truncations 
(A) G-LISA assays measuring the relative amounts of Cdc42-GTP levels in HEK293 
cells expressing myc-tagged wild-type ARHGAP31 (full-length), p.Lys1087SerfsX4 or 
p.Gln683X. Relative Cdc42-GTP values are expressed as a ratio of Cdc42-GTP levels 
found in full-length ARHGAP31. Data are presented as mean ± SEM from 4 independent 
experiments. E.V. = empty vector; **P<0.0002, ***P<0.00001. 
(B) Immunoprecipitation of mouse ARHGAP31 deletion constructs, to map the 
intramolecular interaction between C-terminal amino acids 1083-1425 and the proximal 
221 residues harboring the RhoGAP domain. Full-length protein products are marked by 
the arrows (smaller bands represent degradation products; *IgG light chain). Levels of 
transfected proteins, assessed by Western blotting of the lysates with anti-myc antibody, 
are displayed in the lower panel. 
 
Figure 5. Functional characterization of ARHGAP31 mutations 
(A) Bar chart comparing the proliferative activity of p.Gln683X primary dermal 
fibroblasts (light grey bars) with two distinct control fibroblast cell lines (black and dark 
grey bars). Data represent mean ± SEM for three independent experiments. Statistical 
analysis of each time-point (days 1-9) revealed a significant decrease in the proliferative 
ability of cells carrying the p.Gln683X mutation when compared independently to each of 
the two unaffected controls (*P<0.01). WT = primary dermal fibroblasts from a tissue 
biopsy; HDF = human dermal neonatal fibroblasts. 
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(B) Wound-healing migration assay showing coverage of a cell-free gap by primary 
dermal fibroblasts heterozygous for the p.Gln683X mutation and WT control fibroblasts 
at 24 hours post-wounding. 
(C) Plot showing percentage of wound restoration at 18, 24 and 30 hours post-wounding. 
Fibroblasts heterozygous for the p.Gln683X mutation (light grey bars) migrate at a 
significantly faster rate compared to similar WT control fibroblasts (black bars). Data 
show means ± SEM from three independent experiments. 
(D) HeLa cells transiently transfected with myc-tagged WT ARHGAP31, p.Gln683X and 
p.Lys1087SerfsX4 constructs. Cell shape was visualized by confocal microscopy for 
tubulin (red) and transfected cells identified by co-staining with fluorescent conjugated 
anti-myc antibody (green). DAPI was used to stain the cell nuclei (blue). Rounded cells 
are indicated by the white arrows and 2× higher magnifications of individual cells are 
shown above. 
(E) Bar-chart showing the mean percentage of rounded HeLa cells observed for each 
ARHGAP31 construct from three independent transfection experiments (error bars denote 
SD). 
 
Figure 6. Schematic of disrupted ARHGAP31 signaling 
(A) Schematic representing the putative mechanism of disease. The C-terminus of 
ARHGAP31 inhibits the activity of the RhoGAP domain by specific interaction with 
amino acids 1-221 (red cross symbol). Truncated mutant proteins lacking the C-terminus 
would therefore be incapable of auto-inhibition, resulting in a constitutively active 
RhoGAP domain. 
(B) Schematic of the normal ARHGAP31 signaling system. ARHGAP31 cycles Cdc42 
from an active to an inactive form by hydrolysis of GTP to GDP. GSK-3β upregulates 
30 
ARHGAP31 levels, likely through phosphorylation at a consensus ERK1 site. Activated 
Cdc42 promotes actin polymerization and cellular processes including migration, and acts 
to inhibit GSK-3β activity by stimulating PKCζ phosphorylation of GSK-3β. Wnt 
signaling is an additional negative regulator of GSK-3β activity. Down-regulation of 
GSK-3β leads to decreased proteasomal degradation of cytosolic β-catenin. Active β-
catenin translocates to the nucleus, whereupon the engagement of transcriptional co-
factors controls the differentiation of progenitor cells in the skin. 
(C) In ACC-TTLD mutant cells, constitutive activation of ARHGAP31 leads to an 
imbalance between active and inactive Cdc42. A decrease in the levels of active GTP-
bound Cdc42 results in reduced activation of PKCζ with a concomitant increase in β-
catenin degradation and disruption of cellular processes. 
Key: PKCζ = Protein kinase C; GSK-3β = Glycogen synthase kinase 3 beta; Pi = 
Inorganic phosphate. 
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Supplemental Figure 1: Complete results of the genome-wide linkage scan 
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Graphs representing the combined linkage results for families AOS-5 and AOS-12 across all 22 
autosomes. Chromosome numbers are written above each respective graph. Chromosomal positions 
in Mb, according to the hg19 genome build, are indicated on the x-axis. The y-axis denotes the LOD 
scores, as calculated using Merlin software using genotypes from a total of 5,657 SNPs. The linkage 
peak on chromosome 3q13, containing the ARHGAP31 gene, is the only region that achieves a LOD 
score of genome-wide significance (i.e. LOD ≥ 3), as depicted by the dashed horizontal line in red. 
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Supplemental Figure 2: Refinement mapping and positional cloning of the ACC-TTLD 
phenotype 
 
 
 
 
 
 
 
(A) Segment of chromosome 3, showing linkage results for families AOS-5 and AOS-12 to refine the 
critical interval. Using genotypes from a total of 36 SNPs and 8 microsatellites across 110–130 Mb, a 
maximum multipoint LOD score of 4.93 was achieved at marker rs1464311. The extended 13.2 Mb 
linkage interval examined by exome sequencing is defined by the accepted genome-wide criteria for 
exclusion (i.e. LOD ≤ -2). 
(B) Physical map of the 5.53 Mb critical linkage interval on chromosome 3q13.31-q13.33 (flanked by 
markers rs714697 and D3S4523), showing the 21 genes within the region and the relative location of 
ARHGAP31. The ARHGAP31 gene structure is expanded beneath. 
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Supplemental Figure 3: ARHGAP31 transcript expression 
 
 
 
 
 
 
 
PCR amplification of ARHGAP31 in a human fetal cDNA tissue panel demonstrates global expression 
of the gene. GAPDH primers were used to amplify a 983 bp fragment from all tissues as an internal 
control. Neg = no DNA control. 
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Supplemental Figure 4: Western blot quantification for G-LISA assays 
 
 
 
 
 
 
 
Western blot to determine the levels of tagged proteins and Cdc42 for used in G-LISA assays. A myc-
specific antibody was used to detect WT and mutant (p.Lys1087SerfsX4 and p.Gln683X) proteins. 
E.V. = empty vector. 
 
